UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) ~~of the Securities Exchange Act of 1934~~

~~Date~~ of ~~Report~~the ~~(Date~~Securities ofExchange ~~earliest~~Act ~~event~~of ~~reported): December 4, 2020~~1934

Date of Report (Date of earliest event reported): January 29, 2021

CELLULAR BIOMEDICINE GROUP, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-36498	86-1032927
(State or other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
(State or other Jurisdictionof Incorporation)	(CommissionFile Number)	(IRS EmployerIdentification No.)

209 Perry Parkway, Suite 13 Gaithersburg, Maryland		20877
9605 Medical Center Drive, Suite 100Rockville, MD		20850
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (301) 825-5320

(Former name or former address, if changed since last report.)

209 Perry Parkway, Suite 13

Gaithersburg, MD 20877

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	~~Trading Symbol(s)~~	~~Name of each exchange on which registered~~TradingSymbol(s)		Name of each exchangeon which registered
Common Stock, par value $0.001	~~CBMG~~	~~The Nasdaq Global Select Market~~CBMG		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 78.01 ~~Regulation~~. ~~FD Disclosure~~Other Events.

~~Attached~~As aspreviously ~~Exhibit~~disclosed, ~~99.1~~on toAugust 11, ~~this~~2020, ~~Current~~Cellular ~~Report~~Biomedicine isGroup, Inc. (the ~~form~~“Company” ~~of presentation~~or ~~that~~“CBMG”), ~~Cellular~~a ~~Biomedicine~~Delaware ~~Group~~corporation, ~~Inc.~~entered ~~intends to~~into ~~use~~a indefinitive ~~connection~~merger agreement (the “Merger Agreement”) with aCBMG ~~virtual presentation~~Holdings, toan beexempt ~~held~~company atwith ~~1:15PM~~limited ~~Pacific~~liability ~~Standard~~incorporated ~~Time~~under ~~on Saturday~~the laws of the Cayman Islands (“Parent”), ~~December~~and 5CBMG Merger Sub Inc., ~~2020~~a atDelaware ~~the~~corporation ~~62nd~~and ~~American~~a ~~Society~~wholly-owned subsidiary of ~~Hematology~~ the Parent (~~ASH~~“Merger Sub”), ~~Annual~~pursuant ~~Meeting~~to ~~and~~which ~~Exposition.~~Merger ~~Attached~~Sub aswill ~~Exhibit 99.2~~be tomerged ~~this~~with ~~Current~~and ~~Report~~into isthe Company (the ~~Press~~“Merger”), ~~Release~~with ~~for~~the Company surviving the ~~presentation~~ Merger as a wholly owned subsidiary of Parent.

~~The~~In ~~foregoing~~connection ~~(including~~with ~~Exhibit~~the ~~99.1~~Merger, ~~and~~the ~~Exhibit~~Company ~~99.2) is being furnished pursuant to Item 7.01~~ and ~~will~~Parent ~~not~~filed bea ~~deemed~~joint tovoluntary bedeclaration ~~filed for~~(the ~~purposes~~“Declaration”) ofunder Section 721 18 of the ~~Securities~~Defense ~~and~~Production ~~Exchange~~ Act of ~~1934~~ 1950, as amended (~~the~~ “~~Exchange Act~~DPA”), orwith ~~otherwise be subject to~~ the ~~liabilities~~Committee ofon ~~that~~Foreign ~~section,~~Investment ~~nor~~in ~~will~~the itUnited beStates ~~deemed to~~(“CFIUS”). beCFIUS ~~incorporated~~accepted ~~by reference in any filing under~~ the ~~Securities Act~~Declaration ofon ~~1933~~August 27, ~~as amended, or the Exchange Act~~2020.

~~Item~~On ~~9.01.~~October 21, ~~Financial~~2020, ~~Statements~~the Company and ~~Exhibits~~Parent filed a joint notice under the DPA with CFIUS that was accepted on October 28, 2020. CFIUS conducted a 45-calendar-day review, at the end of which it commenced an additional 45-calendar day investigation of the Merger, pursuant to the DPA.

~~(d) Exhibits~~On January 28, 2021, following the CFIUS review and investigation, the Company and Parent received written notice from CFIUS that it had concluded its review of the Merger and there were no unresolved national security concerns associated with the Merger.

99Receipt of CFIUS clearance satisfies one of the remaining conditions to the closing of the transaction contemplated by the Merger Agreement.~~1 Presentation,~~ ~~dated December~~The 5,Merger ~~2020~~remains subject to receipt of stockholder approval and other customary closing conditions.

99As previously disclosed, the Company will hold a special meeting of the stockholders on February 8, 2021 at 9:00 a.~~2 Press~~m. ~~Release~~Eastern time, ~~dated December~~at 49605 Medical Center Drive, Suite 100, 1st floor, Rockville, Maryland 20850, at which the Company’s stockholders will be asked to consider and vote on, among other things, the proposal to adopt the Merger Agreement and authorize and approve the transactions contemplated thereby, including the Merger. Stockholders of record as of the close of business, Eastern time, on December 18, 2020 will be entitled to vote at the special meeting and any adjournment thereof.

~~104~~The ~~Cover~~Company’s ~~Page~~board ~~Interactive~~of ~~Data~~directors ~~File~~(without the participation of Tony (~~embedded~~Bizuo) ~~within~~Liu, ~~the~~Darren ~~Inline XBRL~~O’Brien ~~document~~and Hansheng Zhou, who abstained from voting given their relationships with Parent), acting upon the unanimous recommendation of the special committee formed by the board of directors, has approved the Merger Agreement, and the transactions contemplated thereby, including the Merger, and recommended that the Company’s stockholders vote in favor of the adoption of the Merger Agreement.

The Company continues to target completion of the Merger in February 2021. However, there can be no assurances regarding the timing or likelihood of the satisfaction of the remaining closing conditions and the consummation of the Merger.

Forward Looking Statements

Statements in this communication relating to plans, strategies, specific activities, and other statements that are not descriptions of historical facts, including our statements regarding the completion of the Merger and targeted timing, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include any risks detailed from time to time in CBMG’s reports filed with the Securities and Exchange Commission, Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, including risks relating to the impact of the COVID-19 pandemic on our operations, including risks associated with the evolving COVID-19 pandemic and actions taken in response to it. Such statements are based on the current beliefs and expectations of the management of CBMG and are subject to significant risks and uncertainties outside of CBMG’s control. These risks and uncertainties include the possibility that the anticipated benefits from the proposed transaction will not be realized, or will not be realized within the expected time periods; the occurrence of any event, change or other circumstances

that could give rise to termination of the Merger Agreement; the failure of CBMG’s stockholders to adopt the Merger Agreement; operating costs, customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, customers, clients or suppliers) may be greater than expected following the announcement of the proposed transaction; the retention of certain key employees at CBMG; risks associated with the disruption of management’s attention from ongoing business operations due to the proposed transaction; the risk that a condition to closing the transaction may not be satisfied on a timely basis or at all; the risk that the proposed transaction fails to close for any other reason; the outcome of any legal proceedings related to the proposed transaction; the parties’ ability to meet expectations regarding the timing and completion of the proposed transaction; the impact of the proposed transaction on the Company’s credit rating; and other risks described in CBMG’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as otherwise required by law, CBMG does not undertake any obligation, and expressly disclaims any obligation, to update, alter or otherwise revise any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future events or otherwise.

Additional Information

This communication may be deemed to be solicitation material in respect of the proposed acquisition of CBMG. In connection with the proposed transaction, CBMG has filed relevant materials with the SEC, including a proxy statement in preliminary and definitive form, in connection with the solicitation of proxies from CBMG’s stockholders for the proposed transaction, and CBMG and certain other persons, including Parent, have filed a Schedule 13E-3 transaction statement with the SEC. The Company first mailed the definitive proxy statement to stockholders entitled to vote at the special meeting on or about December 31, 2020. BEFORE MAKING A VOTING DECISION, STOCKHOLDERS OF CBMG ARE URGED TO READ THE PROXY STATEMENT AND OTHER RELEVANT DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT CBMG, THE PROPOSED TRANSACTION AND RELATED MATTERS. Stockholders may obtain free copies of the proxy statement and other documents that CBMG files with the SEC through the website maintained by the SEC at www.sec.gov. Copies of the documents filed with the SEC by CBMG are also available free of charge on CBMG’s website at https://www.cellbiomedgroup.com or by directing a request to Cellular Biomedicine Group, Inc., Attn: Sarah Kelly, Investor Relations or by calling (301) 825 5320.

Participants in the Solicitation

CBMG and certain of its directors, executive officers and employees may be deemed to be participants in the solicitation of proxies from CBMG’s stockholders in connection with the proposed transaction. Information regarding the ownership of CBMG securities by CBMG’s directors and executive officers is included in their SEC filings on Forms 3, 4 and 5, and additional information about CBMG’s directors and executive officers is also available in CBMG’s proxy statement for its 2020 annual meeting of stockholders filed with the SEC on April 29, 2020 and is supplemented by other filings made, and to be made, with the SEC by CBMG. Additional information regarding persons who may be deemed participants in the solicitation of proxies from CBMG’s stockholders in connection with the proposed transaction, including a description of their respective direct or indirect interests, by security holdings or otherwise, has been included in the proxy statement described above. These documents are or will be available free of charge as described above.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	~~Cellular Biomedicine Group, Inc.~~		Cellular Biomedicine Group, Inc.
Date: December 4, 2020	By:	/s/ Tony (Bizuo) Liu
Date: January 29, 2021			By:	/s/ Andrew Chan
		Tony (Bizuo) Liu
				Andrew Chan
		Chief Executive Officer
				Chief Legal Officer

Filing Compare · Cellular Biomedicine Group, Inc.